Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women.

While the risk for symptomatic atherosclerotic disease increases after menopause, currently recognized risk factors do not identify ongoing disease processes in low-risk women. This study tested the hypothesis that circulating cell-derived microparticles may reflect disease processes in women defined as low risk by the Framingham risk score. The concentration and phenotype of circulating microparticles were evaluated in a cross-sectional study of apparently healthy menopausal women, screened for enrollment into the Kronos Early Estrogen Prevention Study. Microparticles were evaluated by flow cytometry, and coronary artery calcification (CAC) was scored using 64-slice computed tomography scanners. The procoagulant activity of isolated microparticles was determined with a sensitive fluorescent thrombin generation assay. Chronological age, body mass index, serum lipids, systolic blood pressure (Framingham risk score < 10%, range 1-3%), and high-sensitivity C-reactive protein did not differ significantly among women with low (0 < 35; range, 0.3-32 Agatston units) or high (>50; range, 93-315 Agatston units) CAC compared with women without calcification. The total concentration and percentage of microparticles derived from platelets and endothelial cells were greatest in women with high CAC scores. The thrombin-generating capacity of the isolated microparticles correlated with phosphatidylserine expression, which also was greatest in women with high CAC scores. The percentages of microparticles expressing granulocyte and monocyte markers were not significantly different among groups. Therefore, the characterization of platelet and endothelial microparticles may identify early menopausal women with premature CAC who would not otherwise be identified by the usual risk factor analysis.

[1]  David M Herrington,et al.  Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). , 2007, Archives of internal medicine.

[2]  R. Turner,et al.  Endochondral bone formation in the heart: a possible mechanism of coronary calcification. , 2003, Endocrinology.

[3]  Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events , 2006 .

[4]  Y. Tintut,et al.  Recent advances in multifactorial regulation of vascular calcification , 2001, Current opinion in lipidology.

[5]  V. Miller,et al.  In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. , 2007, Journal of applied physiology.

[6]  A. Simon,et al.  Circulating Leukocyte-Derived Microparticles Predict Subclinical Atherosclerosis Burden in Asymptomatic Subjects , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Schroit,et al.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. , 1997, Blood.

[8]  O. Tawfik,et al.  Mechanisms of calcification by vesicles isolated from atherosclerotic rabbit aortas. , 2002, Biochimica et biophysica acta.

[9]  L. Horstman,et al.  Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. , 2003, Thrombosis research.

[10]  P. Ridker C-reactive protein, inflammation, and cardiovascular disease: clinical update. , 2005, Texas Heart Institute journal.

[11]  R. Ross,et al.  Cell biology of atherosclerosis. , 1995, Annual review of physiology.

[12]  J. Manson,et al.  KEEPS: The Kronos Early Estrogen Prevention Study , 2005, Climacteric : the journal of the International Menopause Society.

[13]  R. Paltriccia,et al.  Increased Ratio of CD31+/CD42− Microparticles to Endothelial Progenitors as a Novel Marker of Atherosclerosis in Hypercholesterolemia , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Chantal M Boulanger,et al.  Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[15]  R. Nieuwland,et al.  Microparticles in cardiovascular diseases. , 2003, Cardiovascular research.

[16]  H Kuhl,et al.  Pharmacology of estrogens and progestogens: influence of different routes of administration , 2005, Climacteric : the journal of the International Menopause Society.

[17]  M. Budoff,et al.  Underlying risk factors incrementally add to the standard risk estimate in detecting subclinical atherosclerosis in low- and intermediate-risk middle-aged asymptomatic individuals. , 2004, American heart journal.

[18]  L. Horstman,et al.  Endothelial microparticles as markers of endothelial dysfunction. , 2004, Frontiers in bioscience : a journal and virtual library.

[19]  R. Bing,et al.  Release of Endothelium‐Derived Relaxing Factor From Freshly Harvested Porcine Endothelial Cells , 1987, Circulation research.

[20]  J. Lieske,et al.  Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. , 2004, American journal of physiology. Heart and circulatory physiology.

[21]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[22]  F. Dignat-George,et al.  Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. , 1997, Tissue antigens.

[23]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[24]  S. Reis,et al.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. , 2006, Journal of the American College of Cardiology.

[25]  Carl J Pepine,et al.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. , 2006, Journal of the American College of Cardiology.

[26]  Y. Castier,et al.  Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. , 2007, Journal of the American College of Cardiology.

[27]  J. Freyssinet,et al.  Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[28]  D. Pisetsky,et al.  Microparticles as mediators of cellular cross-talk in inflammatory disease , 2006, Autoimmunity.

[29]  J. Manson,et al.  Estrogen therapy and coronary-artery calcification. , 2007, The New England journal of medicine.

[30]  J. Freyssinet,et al.  Cellular microparticles: a disseminated storage pool of bioactive vascular effectors , 2004, Current opinion in hematology.

[31]  W. Grossman,et al.  Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[32]  A. Mügge,et al.  Circulating endothelial microparticles correlate inversely with endothelial function in patients with ischemic left ventricular dysfunction. , 2008, Journal of cardiac failure.

[33]  D. Goldstein,et al.  Drug‐metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests , 2005, Clinical pharmacology and therapeutics.

[34]  R. Detrano,et al.  Genetic determinants of arterial calcification associated with atherosclerosis. , 2004, Mayo Clinic proceedings.

[35]  C. Ludlam,et al.  Plasma microparticles and vascular disorders , 2007, British journal of haematology.

[36]  G. Nickenig,et al.  Circulating CD 31 / Annexin V Apoptotic Microparticles Correlate With Coronary Endothelial Function in Patients With Coronary Artery Disease , 2005 .

[37]  A. Tedgui,et al.  Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. , 2006, Hypertension.

[38]  C. Hack,et al.  Cell-derived Microparticles Circulate in Healthy Humans and Support Low Grade Thrombin Generation , 2001, Thrombosis and Haemostasis.

[39]  V. Fuster,et al.  Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis , 2004, Journal of Thrombosis and Thrombolysis.

[40]  R. Kronmal,et al.  Implications of C-reactive protein or coronary artery calcium score as an adjunct to global risk assessment for primary prevention of CHD. , 2007, Atherosclerosis.

[41]  P. Libby Inflammation in atherosclerosis , 2002, Nature.

[42]  P. J. Newman,et al.  The biology of PECAM-1. , 1997, The Journal of clinical investigation.

[43]  Nikos Werner,et al.  Circulating CD31+/Annexin V+ Apoptotic Microparticles Correlate With Coronary Endothelial Function in Patients With Coronary Artery Disease , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[44]  A. Tedgui,et al.  Circulating Microparticles From Patients With Myocardial Infarction Cause Endothelial Dysfunction , 2001, Circulation.

[45]  McDowell Em,et al.  Histologic fixatives suitable for diagnostic light and electron microscopy. , 1976 .

[46]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.